Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX.
Brief Summary: The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an incomplete response to MTX. The pharmacokinetics and immunogenicity profile of CDP870 will also be investigated to assess the extrapolability of foreign data to the Japanese population.


Options:
A: Arm Label: CDP870 100mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 100mg | Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 200mg | Arm Label: CDP870 400mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 400mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870 400mg; Assigned to Arm(s): CDP870 400mg | Intervention Type: DRUG; Name: CDP870 200mg; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: CDP870 100mg; Assigned to Arm(s): CDP870 100mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
B: Arm Label: Subcutaneous (SC) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Subcutaneous (SC) Abatacept | Arm Label: Intravenous (IV) Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) Abatacept | Intervention Type: DRUG; Name: Subcutaneous (SC) Abatacept; Assigned to Arm(s): Subcutaneous (SC) Abatacept | Intervention Type: DRUG; Name: Intravenous (IV) Abatacept; Assigned to Arm(s): Intravenous (IV) Abatacept
C: Arm Label: Group I: 2mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group II: 2mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group III: 4mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group IV: 4mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group V: IV Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group II: 2mg/kg Golimumab only, Group III: 4mg/kg Golimumab + MTX, Group IV: 4mg/kg Golimumab only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group III: 4mg/kg Golimumab + MTX, Group V: IV Placebo + MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group II: 2mg/kg Golimumab only, Group IV: 4mg/kg Golimumab only, Group V: IV Placebo + MTX
D: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: BMS-945429 Placebo, Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 5; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate Placebo, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 6; Type: EXPERIMENTAL; Interventions: Biological: BMS-945429, Drug: Methotrexate Placebo, Drug: Methotrexate, Drug: Adalimumab Placebo | Arm Label: Arm 7; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Adalimumab | Intervention Type: DRUG; Name: BMS-945429 Placebo; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 4 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 3, Arm 6 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 1, Arm 4 | Intervention Type: BIOLOGICAL; Name: BMS-945429; Assigned to Arm(s): Arm 2, Arm 5 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm 2, Arm 3, Arm 4, Arm 7 | Intervention Type: DRUG; Name: Methotrexate Placebo; Assigned to Arm(s): Arm 5, Arm 6 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Arm 5, Arm 6 | Intervention Type: DRUG; Name: Adalimumab Placebo; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4, Arm 5, Arm 6 | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Arm 7

Answer: A